RPS6KA1 and acute myeloid leukemia: To further characterize the role of RPS6KA1 as a mediator of proliferation and therapy resistance in AML, we performed functional assays using pharmacological inhibition of RPS6KA1 with the RSK inhibitor BI-D1870.